Skystar Bio-Pharmaceutical Company (SKBI) 0.1535

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 11:22 PM

Skystar Bio-Pharmaceutical Company (SKBI) 0.1535 $SKBI

Skystar Bio-Pharmaceutical Company Update
Marketwired - Tue Dec 22, 9:17AM CST
Skystar Bio-Pharmaceutical Company (OTCQB: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that while the Company trades on the over-the-counter market, it has made progress with its audits.

Skystar Bio-Pharmaceutical Company Announces Delisting From NASDAQ
Marketwired - Fri Dec 18, 3:30PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on December 17, 2015, Skystar Bio-Pharmaceutical Company (the "Company"

received notification from The Nasdaq Stock Market ("Nasdaq"

informing the Company that a Nasdaq hearing panel had decided to delist the Company's shares from Nasdaq and that the Company's shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015.

Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Notification Letter
Marketwired - Thu Nov 19, 10:57AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on November 17, 2015, it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq's filing requirement set forth in Listing Rule 5250(c)(1) (the "Rule"

because it failed to file its Form 10-Q for the fiscal quarter ended September 30, 2015 (the "Quarterly Report"

.

Skystar Bio-Pharmaceutical Company Request to Stay Nasdaq Trading Suspension Granted
Marketwired - Fri Nov 06, 8:00AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on November 4, 2015 it received a letter from the Nasdaq Hearings Panel that granted the request of Skystar Bio-Pharmaceutical Company to extend the automatic 15-day stay of suspension from The Nasdaq Stock Market, until the hearing on the merits scheduled for December 3, 2015, and a determination regarding the Company's listing status.

Skystar Bio-Pharmaceutical Company Provides Investor Update Regarding Delay in Filing Form 10-K
Marketwired - Fri Oct 02, 8:30AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that it has conferred with Crowe Horwath, HK, the Company's appointed auditor in relation to the completion of Skystar's audit for the year ended December 31, 2014 and the review of the Company's financial statements for the quarters ended March 31, 2015 and June 30, 2015. Based on those communications, Skystar believes that Crowe Horwath is in the process of completing its audit of the Company's financial statements for the year ended December 31, 2014.

Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in Filing Form 10-Q
Marketwired - Tue Aug 25, 3:15PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on August 19, 2015, the Company received a notification from the Nasdaq Stock Market ("Nasdaq"

informing the Company that because it had not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Company previously submitted a plan of compliance to Nasdaq, responded to an initial request for additional information from Nasdaq, and is preparing responses to a second request for additional information from Nasdaq. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the date of its initial delinquent filing (its Annual Report on Form 10-K for the year ended December 31, 2014), or until October 12, 2015, to regain compliance.

Skystar Bio-Pharmaceutical Company Announces Submission of Plan of Compliance With Nasdaq
Marketwired - Mon Jun 15, 9:32PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company timely submitted a "Plan of Compliance" to Nasdaq in accordance with applicable Nasdaq rules. The Plan of Compliance sets out the Company's plan to regain compliance with Nasdaq's continued listing rules.

Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K
Marketwired - Wed Apr 15, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market ("Nasdaq"

informing the Company that since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2014, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted under its current trading symbol.

Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Giese Foundation Boosts Cancer Support Services Reach

When cancer pays an unwelcome visit to a family, it doesn’t come alone. It drags along fear, uncertainty, and bruising challenges. And as support needs balloon, thankfully there's a beacon like the Brian & Patricia Giese Foundation stepping up to sustain vital programs. Understanding the Real Impact Now, listen up. Cancer may target one body, but its claws reach...

Gillis Joins McGinnis Lochridge as COO Amid Firm's Milestone

An Experienced Executor at the Helm Now, here's a story that rings of continuity meeting change. McGinnis Lochridge, a staple of the Texas legal scene since 1927, has tapped Charles Gillis to take charge as their Chief Operating Officer. You'd think they're gearing up to celebrate a hundred years by shaking things up internally. Why not bring in someone seasoned, I say?...

InfraMed Expands Team for National Healthcare Growth

InfraMed's Bold Move in Healthcare Real Estate You know, it’s not every day you see a company go all in on healthcare properties like InfraMed’s doing. With the blitz of new personnel, we're talking about a genuine push to carve out a piece of the national market. And if you've been keeping tabs, this isn't just a hunch—they've got serious momentum brewing, and the...

Roofr Unveils AI Tools: Shaping Roofing's Future

Making Waves in Roofing: Roofr's Big Moves Listen up, folks. When a company like Roofr announces new tech, contractors better pay attention. The roofing industry—often overlooked by the flashy tech scene—just got hit with some slick new tools. Today, Roofr held its semi-annual virtual event, Roofr Builds, unraveling a slew of updates that might just streamline the way...

Escalade to Unveil Q3 2026 Results and Host Call

Details on Escalade's Upcoming Financial Revelation Evansville's own Escalade, Inc. (NASDAQ: ESCA) is set to drop its third quarter 2026 financial results on October 29, well before your breakfast is done. For anyone following this stock, it's like waiting for the last few seconds of a tied basketball game. This isn’t just about numbers – it’s about a whole host of...

Green Builder Media's Fresh Focus on Net Zero Homes

There's a fresh breeze blowing through the building industry, and it's got "net zero" written all over it. Green Builder Media is rolling out a pile of new resources aimed at wrangling this beast of a trend. The focus? High-performance, all-electric homes. And they're not just whispering about it—they've got hard data and practical guidance to back up their claims. Net...

OTconnect on Apple Watch: A New Fitness Era Dawns

What’s Orangetheory Up To Now? Ah, fitness gadgets, where everyone’s seemingly got a scheme brewing. This time it's Orangetheory (OTF), turning your Apple Watch into your new best gym buddy. October 22, 2026, marks the launch of OTconnect for Apple Watch, offering a slick way for enthusiasts to tune into their own sweat metrics. If you’re already an Apple Watch...

US Myeloma Network Revolutionizes Cancer Trials in U.S.

New Era for Myeloma Research In a move set to shake up the oncology world, the International Myeloma Foundation (IMF) is lighting a fire under clinical research with its ambitious US Myeloma Network (USMN). The whole shebang is about supercharging clinical trials and bringing real hope to folks battling multiple myeloma. If you've been watching the space, you know we're...

Rising Demand for Natural Fibres: Woolmark's Bold Move

A Shift Toward Nature-Driven Choices There's something brewing in the fashion world that signals a deeper shift—a movement toward fibers that feel real, fibers that nature and time have refined. Recent Ipsos research commissioned by Woolmark has laid bare the growing consumer preference across major markets, with a distinct swing towards natural fibers, leaving...

Fort Point Capital Sells AMS Fulfillment to Stord

Fort Point Capital's Strategic Play Just when you thought the game was getting stale, Fort Point Capital dropped a bomb: they’ve sold AMS Fulfillment to Stord. This isn't just some late-season punt; it's a calculated play from a Boston-based private equity player known for snapping up and scaling service-oriented businesses in the lower middle market. It's like...